Fibrinolytic agents for the management of ST-segment elevation myocardial infarction

Daniel E. Hilleman, James P. Tsikouris, A. Allen Seals, Jonathan D. Marmur

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Rapid reperfusion is the key treatment goal in patients with ST-segment elevation myocardial infarction (STEMI). The American College of Cardiology-American Heart Association (ACC-AHA) 2004 guidelines for the management of STEMI include recommendations for pharmacologic reperfusion with use of fibrinolytic agents. Fibrinolytic agents are the preferred pharmacologic class for the management of STEMI because of their ability to achieve reperfusion and to restore blood flow when administered within 12 hours of symptom onset. Four fibrinolytic agents are approved for the treatment of STEMI in the United States - streptokinase, alteplase, reteplase, and tenecteplase. Several clinical trials have demonstrated the beneficial effects of these therapies in reducing mortality rates in patients with suspected acute myocardial infarction. Alteplase is administered as an intravenous infusion. However, the relatively long half-lives of reteplase and tenecteplase enable bolus administration, which may be more convenient and less time consuming. Reteplase is administered as a double bolus, and dosing does not depend on the patient's weight; tenecteplase is administered as a single bolus, and dosing is weight based. Adherence to the ACC-AHA guidelines, as well as knowledge about the available fibrinolytic agents, is essential for physicians and pharmacists to make informed decisions regarding appropriate pharmacologic reperfusion strategies.

Original languageEnglish
Pages (from-to)1558-1570
Number of pages13
JournalPharmacotherapy
Volume27
Issue number11
DOIs
StatePublished - Nov 2007

Fingerprint

Fibrinolytic Agents
Reperfusion
Tissue Plasminogen Activator
Guidelines
American Heart Association
Weights and Measures
Streptokinase
Cardiology
Pharmacists
Intravenous Infusions
Therapeutics
Myocardial Infarction
Clinical Trials
Physicians
Mortality
ST Elevation Myocardial Infarction
reteplase
tenecteplase

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. / Hilleman, Daniel E.; Tsikouris, James P.; Seals, A. Allen; Marmur, Jonathan D.

In: Pharmacotherapy, Vol. 27, No. 11, 11.2007, p. 1558-1570.

Research output: Contribution to journalReview article

Hilleman, Daniel E. ; Tsikouris, James P. ; Seals, A. Allen ; Marmur, Jonathan D. / Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. In: Pharmacotherapy. 2007 ; Vol. 27, No. 11. pp. 1558-1570.
@article{4c6c5b91788741e685763563af084e87,
title = "Fibrinolytic agents for the management of ST-segment elevation myocardial infarction",
abstract = "Rapid reperfusion is the key treatment goal in patients with ST-segment elevation myocardial infarction (STEMI). The American College of Cardiology-American Heart Association (ACC-AHA) 2004 guidelines for the management of STEMI include recommendations for pharmacologic reperfusion with use of fibrinolytic agents. Fibrinolytic agents are the preferred pharmacologic class for the management of STEMI because of their ability to achieve reperfusion and to restore blood flow when administered within 12 hours of symptom onset. Four fibrinolytic agents are approved for the treatment of STEMI in the United States - streptokinase, alteplase, reteplase, and tenecteplase. Several clinical trials have demonstrated the beneficial effects of these therapies in reducing mortality rates in patients with suspected acute myocardial infarction. Alteplase is administered as an intravenous infusion. However, the relatively long half-lives of reteplase and tenecteplase enable bolus administration, which may be more convenient and less time consuming. Reteplase is administered as a double bolus, and dosing does not depend on the patient's weight; tenecteplase is administered as a single bolus, and dosing is weight based. Adherence to the ACC-AHA guidelines, as well as knowledge about the available fibrinolytic agents, is essential for physicians and pharmacists to make informed decisions regarding appropriate pharmacologic reperfusion strategies.",
author = "Hilleman, {Daniel E.} and Tsikouris, {James P.} and Seals, {A. Allen} and Marmur, {Jonathan D.}",
year = "2007",
month = "11",
doi = "10.1592/phco.27.11.1558",
language = "English",
volume = "27",
pages = "1558--1570",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "11",

}

TY - JOUR

T1 - Fibrinolytic agents for the management of ST-segment elevation myocardial infarction

AU - Hilleman, Daniel E.

AU - Tsikouris, James P.

AU - Seals, A. Allen

AU - Marmur, Jonathan D.

PY - 2007/11

Y1 - 2007/11

N2 - Rapid reperfusion is the key treatment goal in patients with ST-segment elevation myocardial infarction (STEMI). The American College of Cardiology-American Heart Association (ACC-AHA) 2004 guidelines for the management of STEMI include recommendations for pharmacologic reperfusion with use of fibrinolytic agents. Fibrinolytic agents are the preferred pharmacologic class for the management of STEMI because of their ability to achieve reperfusion and to restore blood flow when administered within 12 hours of symptom onset. Four fibrinolytic agents are approved for the treatment of STEMI in the United States - streptokinase, alteplase, reteplase, and tenecteplase. Several clinical trials have demonstrated the beneficial effects of these therapies in reducing mortality rates in patients with suspected acute myocardial infarction. Alteplase is administered as an intravenous infusion. However, the relatively long half-lives of reteplase and tenecteplase enable bolus administration, which may be more convenient and less time consuming. Reteplase is administered as a double bolus, and dosing does not depend on the patient's weight; tenecteplase is administered as a single bolus, and dosing is weight based. Adherence to the ACC-AHA guidelines, as well as knowledge about the available fibrinolytic agents, is essential for physicians and pharmacists to make informed decisions regarding appropriate pharmacologic reperfusion strategies.

AB - Rapid reperfusion is the key treatment goal in patients with ST-segment elevation myocardial infarction (STEMI). The American College of Cardiology-American Heart Association (ACC-AHA) 2004 guidelines for the management of STEMI include recommendations for pharmacologic reperfusion with use of fibrinolytic agents. Fibrinolytic agents are the preferred pharmacologic class for the management of STEMI because of their ability to achieve reperfusion and to restore blood flow when administered within 12 hours of symptom onset. Four fibrinolytic agents are approved for the treatment of STEMI in the United States - streptokinase, alteplase, reteplase, and tenecteplase. Several clinical trials have demonstrated the beneficial effects of these therapies in reducing mortality rates in patients with suspected acute myocardial infarction. Alteplase is administered as an intravenous infusion. However, the relatively long half-lives of reteplase and tenecteplase enable bolus administration, which may be more convenient and less time consuming. Reteplase is administered as a double bolus, and dosing does not depend on the patient's weight; tenecteplase is administered as a single bolus, and dosing is weight based. Adherence to the ACC-AHA guidelines, as well as knowledge about the available fibrinolytic agents, is essential for physicians and pharmacists to make informed decisions regarding appropriate pharmacologic reperfusion strategies.

UR - http://www.scopus.com/inward/record.url?scp=35848946373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848946373&partnerID=8YFLogxK

U2 - 10.1592/phco.27.11.1558

DO - 10.1592/phco.27.11.1558

M3 - Review article

VL - 27

SP - 1558

EP - 1570

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 11

ER -